Haemonetics Corporation (HAE)

Return on equity (ROE)

		Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020
Net income (ttm)	US$ in thousands	167,679	130,065	123,812	114,889	117,558	126,574	128,277	136,566	115,401	95,759	86,047	67,706	43,375	22,593	31,243	64,488	79,469	108,134	106,147	95,532
Total stockholders’ equity	US$ in thousands	951,605	906,860	878,851	905,368	959,959	943,319	893,660	864,616	817,997	775,979	729,009	770,423	749,424	730,775	698,549	677,080	731,670	719,152	667,923	608,569
ROE		17.62%	14.34%	14.09%	12.69%	12.25%	13.42%	14.35%	15.79%	14.11%	12.34%	11.80%	8.79%	5.79%	3.09%	4.47%	9.52%	10.86%	15.04%	15.89%	15.70%

March 31, 2025 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $167,679K ÷ $951,605K
= 17.62%

Haemonetics Corporation's return on equity (ROE) has shown fluctuations over the period from June 30, 2020, to March 31, 2025.

The ROE was relatively stable between June 30, 2020, and March 31, 2021, ranging from 15.70% to 10.86%. However, there was a noticeable decline in ROE in subsequent quarters, reaching a low of 3.09% by December 31, 2021. This downward trend continued until March 31, 2022, when the ROE increased to 5.79%.

From June 30, 2022, to March 31, 2025, Haemonetics Corporation's ROE showed an improving trend, gradually increasing from 8.79% to 17.62% by the end of March 2025. This indicates a positive development in the company's ability to generate profits from shareholders' equity.

Overall, the fluctuation in ROE over the period suggests that Haemonetics Corporation has experienced varying levels of profitability relative to its equity base. The recent uptrend in ROE is a positive indication of the company's improving financial performance and efficiency in utilizing shareholders' equity to generate returns.